Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rucha V. Modak"'
Autor:
Karl K. Weitz, Hutchinson-Bunch C, Rucha V. Modak, Sunil K. Joshi, Marina A. Gritsenko, Cristina E. Tognon, Drucker B, Anupriya Agarwal, Paul D. Piehowski, Karin D. Rodland, Jamie Moon, Hansen, Alisa Damnernsawad, Elie Traer, Sara J Gosline, Jason E. McDermott, Nestor M
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f0195ca82f2684b9e1e06b2576b3ad
https://doi.org/10.1101/2021.06.04.447154
https://doi.org/10.1101/2021.06.04.447154
Autor:
Guanming Wu, Sara J Gosline, Paul D. Piehowski, Ted Laderas, Shannon K. McWeeney, Alisa Damnernsawad, Tamilla Nechiporuk, Christopher A. Eide, Jeffrey W. Tyner, Anupriya Agarwal, Rucha V. Modak, Karin D. Rodland, Stephen E. Kurtz
Publikováno v:
Blood. 136:11-12
Background: The treatment of acute myeloid leukemia (AML) patients is a formidable challenge, due to disease heterogeneity and the ability to acquire secondary mutations in response to treatment. As a result, persistence and expansion of residual AML
Autor:
Dietmar M. W. Zaiss, Rucha V. Modak
Publikováno v:
Modak, R & Zaiss, D 2019, ' Isolation and culture of murine hepatic stellate cells ', Bio-protocol . https://doi.org/10.21769/BioProtoc.3422
Hepatic stellate cells (HSCs), alternatively known as liver pericytes, can differentiate into myofibroblasts and secrete extra-cellular matrix components, thereby promoting wound healing and fibrosis. Studying HSCs can provide insights into the patho
Autor:
Ted Laderas, Shannon K. McWeeney, Jeffery W. Tyner, Rucha V. Modak, Guanming Wu, Karin D. Rodland, Alisa Damnernsawad, Anupriya Agarwal
Publikováno v:
Cancer Research. 80:5942-5942
Background: Acute myeloid leukemia (AML) is a heterogeneous disease with a dismal 5 year survival rate below 30%. Current AML therapies have provided little improvement in achieving complete remission. This is attributed to the development of drug re